Pharmacological Inhibition of LRRK2 Exhibits Neuroprotective Activity in Mouse Photothrombotic Stroke Model

Overview

Journal Exp Neurobiol

Specialty Neurology

Date 2024 Mar 12

PMID 38471803

Authors

Jeong-Ah Hwang

Seung Kyu Choi

Seong Hwan Kim

Dong Woon Kim

Affiliations

Soon will be listed here.

Abstract

Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common cause of Parkinson's disease (PD). Interestingly, recent studies have reported an increased risk of stroke in patients with PD harboring LRRK2 mutations, but there is no evidence showing the functional involvement of LRRK2 in stroke. Here, we found that LRRK2 kinase activity was significantly induced in the Rose-Bengal (RB) photothrombosis-induced stroke mouse model. Interestingly, stroke infarct volumes were significantly reduced, and neurological deficits were diminished by pharmacological inhibition of LRRK2 kinase activity using MLi-2, a brain-penetrant LRRK2 kinase inhibitor. Immunohistochemical analysis showed p-LRRK2 level in stroke lesions, co-localizing with mitophagy-related proteins (PINK, Parkin, LC3B, cytochrome c), suggesting their involvement in stroke progression. Overlapping p-LRRK2 with cytochrome c/TUNEL/JC-1 (an indicator of mitochondrial membrane potential) puncta in RB photothrombosis indicated LRRK2-induced mitochondrial apoptosis, which was blocked by MLi-2. These results suggest that pharmacological inhibition of LRRK2 kinase activity could attenuate mitochondrial apoptosis, ultimately leading to neuroprotective potential in stroke progression. In conclusion, LRRK2 kinase activity might be neuro-pathogenic due to impaired mitophagy in stroke progression, and pharmacological inhibition of LRRK2 kinase activity could be beneficial in reducing the risk of stroke in patients with LRRK2 mutations.

References

Coon E, Cutsforth-Gregory J, Benarroch E . Neuropathology of autonomic dysfunction in synucleinopathies. Mov Disord. 2018; 33(3):349-358. DOI: 10.1002/mds.27186. View

Yang G, Chan P, Chen J, Carlson E, Chen S, Weinstein P . Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. Stroke. 1994; 25(1):165-70. DOI: 10.1161/01.str.25.1.165. View

Nixon R, Wegiel J, Kumar A, Yu W, Peterhoff C, Cataldo A . Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005; 64(2):113-22. DOI: 10.1093/jnen/64.2.113. View

Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M . Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature. 2014; 510(7503):162-6. DOI: 10.1038/nature13392. View

Godena V, Brookes-Hocking N, Moller A, Shaw G, Oswald M, Sancho R . Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat Commun. 2014; 5:5245. PMC: 4208097. DOI: 10.1038/ncomms6245. View

Carmichael S . Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx. 2006; 2(3):396-409. PMC: 1144484. DOI: 10.1602/neurorx.2.3.396. View

Pickrell A, Youle R . The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015; 85(2):257-73. PMC: 4764997. DOI: 10.1016/j.neuron.2014.12.007. View

Kawajiri S, Saiki S, Sato S, Sato F, Hatano T, Eguchi H . PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy. FEBS Lett. 2010; 584(6):1073-9. DOI: 10.1016/j.febslet.2010.02.016. View

Reers M, Smith T, Chen L . J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry. 1991; 30(18):4480-6. DOI: 10.1021/bi00232a015. View

10.

Narendra D, Tanaka A, Suen D, Youle R . Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008; 183(5):795-803. PMC: 2592826. DOI: 10.1083/jcb.200809125. View

11.

Hsieh C, Shaltouki A, Gonzalez A, Bettencourt da Cruz A, Burbulla L, St Lawrence E . Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson's Disease. Cell Stem Cell. 2016; 19(6):709-724. PMC: 5135570. DOI: 10.1016/j.stem.2016.08.002. View

12.

Wauters F, Cornelissen T, Imberechts D, Martin S, Koentjoro B, Sue C . mutations impair depolarization-induced mitophagy through inhibition of mitochondrial accumulation of RAB10. Autophagy. 2019; 16(2):203-222. PMC: 6984591. DOI: 10.1080/15548627.2019.1603548. View

13.

Macias-Garcia D, Perinan M, Munoz-Delgado L, Jesus S, Jimenez-Jaraba M, Buiza-Rueda D . Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations. Mov Disord. 2021; 37(1):225-227. DOI: 10.1002/mds.28863. View

14.

Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A . Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis. 2006; 23(2):329-41. DOI: 10.1016/j.nbd.2006.04.001. View

15.

Suri J, Paul S, Maindarkar M, Puvvula A, Saxena S, Saba L . Cardiovascular/Stroke Risk Stratification in Parkinson's Disease Patients Using Atherosclerosis Pathway and Artificial Intelligence Paradigm: A Systematic Review. Metabolites. 2022; 12(4). PMC: 9033076. DOI: 10.3390/metabo12040312. View

16.

Kluss J, Mazza M, Li Y, Manzoni C, Lewis P, Cookson M . Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo. Mol Neurodegener. 2021; 16(1):17. PMC: 7977595. DOI: 10.1186/s13024-021-00441-8. View

17.

Sapp E, Schwarz C, Chase K, Bhide P, Young A, Penney J . Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol. 1997; 42(4):604-12. DOI: 10.1002/ana.410420411. View

18.

Bae Y, Joo H, Bae J, Hyeon S, Her S, Ko E . Brain injury induces HIF-1α-dependent transcriptional activation of LRRK2 that exacerbates brain damage. Cell Death Dis. 2018; 9(11):1125. PMC: 6232134. DOI: 10.1038/s41419-018-1180-y. View

19.

Smith W, Pei Z, Jiang H, Dawson V, Dawson T, Ross C . Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci. 2006; 9(10):1231-3. DOI: 10.1038/nn1776. View

20.

Paisan-Ruiz C, Jain S, Evans E, Gilks W, Simon J, van der Brug M . Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004; 44(4):595-600. DOI: 10.1016/j.neuron.2004.10.023. View